Clinigen

Market Access

MAPs, EAPs, and patient access: Suzanne Aitken on the challe...

Suzanne Aitken, SVP of managed access at Clinigen, discussing the role of managed access programmes in the current pharmaceutical landscape.

R&D

The backbone of breakthroughs: Insights into clinical trial ...

Behind every successfully approved treatment lies a nexus of clinical research activities comprising myriad drug types, trial phases, and packaging needs across diverse geographical locatio

News

Clinigen educates on early access to rare disease therapies

On Rare Disease Day, Clinigen has launched a campaign to try to encourage doctors and patients to explore how they can get early access to investigational therapies.

News

Clinigen launches scheme to support rare disease patients

Clinigen has launched a new programme in the UK that aims to help organisations representing patients with rare diseases participate in R&D for new medicines and suppo

News

Packaged Pills in aluminium blisters stacked on each other

Clinigen buys remaining rights to Novartis cancer drug

UK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up to $210 million.

MAPs, EAPs, and patient access: Suzanne Aitken on the challe...

The backbone of breakthroughs: Insights into clinical trial ...

Clinigen educates on early access to rare disease therapies

Clinigen launches scheme to support rare disease patients

Clinigen buys remaining rights to Novartis cancer drug

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

Clinigen

Editor's Picks